Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
natural killer cell + ViroCure oncolytic virus
- Development stage
- Preclinical
- Lead developer
- ViroCure
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravesical, Intravenous
01
Overview
This combination therapy, developed by ViroCure Australia in partnership with ViroCure Inc., involves the synergistic use of Natural Killer (NK) cells and a proprietary oncolytic virus, typically a strain of Reovirus (Mammalian orthoreovirus). The oncolytic virus is designed to selectively infect and replicate within cancer cells—particularly those with activated Ras signaling pathways—leading to direct cell lysis (oncolysis). This process releases tumor-associated antigens and pro-inflammatory cytokines into the tumor microenvironment, which "warms up" the tumor and enhances the recruitment and activation of the co-administered NK cells. The NK cells then exert potent cytotoxic effects against the remaining tumor cells, providing a dual-action approach to overcome the immunosuppressive environment of solid tumors. The program is currently in preclinical development for the treatment of bladder cancer.
- Other names
- NK cell + oncolytic virus combinationnatural killer cell + ViroCure oncolytic virus combination
Beyond the preview
Go deeper on natural killer cell + ViroCure oncolytic virus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on natural killer cell + ViroCure oncolytic virus.